Spots Global Cancer Trial Database for cabazitaxel
Every month we try and update this database with for cabazitaxel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | NCT02522715 | Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone | 18 Years - | OHSU Knight Cancer Institute | |
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | NCT04592237 | Aggressive Vari... Castration-Resi... Metastatic Pros... Metastatic Pros... Metastatic Pros... Stage IV Prosta... | Cabazitaxel Carboplatin Cetrelimab Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel | NCT01668459 | Transitional Ce... | Cabazitaxel Best Supportive... | 18 Years - | University Hospital Birmingham NHS Foundation Trust | |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | NCT02202772 | Urothelial Carc... | Cabazitaxel Gemcitabine Cisplatin | 18 Years - | Columbia University | |
| Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | NCT01757171 | Gastric Adenoca... Gastroesophagea... Distal Esophage... | Cabazitaxel | 18 Years - | Weill Medical College of Cornell University | |
| Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | NCT02254785 | Metastatic Cast... | cabazitaxel Abiraterone Enzalutamide 16... | 18 Years - | British Columbia Cancer Agency | |
| Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic | NCT03101046 | Prostate Carcin... Castration-resi... Circulating Tum... Chemotherapy | Cabazitaxel Docetaxel | 18 Years - | UNICANCER | |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | NCT06085729 | Prostate Cancer | ADI-PEG 20 Cabazitaxel Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes | NCT01693549 | Breast Cancer | Cabazitaxel | 18 Years - 75 Years | Hellenic Cooperative Oncology Group | |
| Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | NCT01531205 | Prostate Cancer | Androgen Ablati... Cabazitaxel Salvage Therapy Neoadjuvant Tre... Neoadjuvant Tre... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | NCT05818683 | Metastatic Cast... | JNJ-78278343 Cetrelimab Cabazitaxel Docetaxel Apalutamide Enzalutamide Darolutamide Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | NCT01934894 | Metastatic Brea... | cabazitaxel lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | NCT01531205 | Prostate Cancer | Androgen Ablati... Cabazitaxel Salvage Therapy Neoadjuvant Tre... Neoadjuvant Tre... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome | NCT04622761 | Prostate Cancer | Cabazitaxel | 18 Years - | The Clatterbridge Cancer Centre NHS Foundation Trust | |
| Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel | NCT02961257 | Prostate Cancer... | cabazitaxel Prednisone Granulocyte col... | 65 Years - | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | NCT01469338 | Diarrhea Hormone-resista... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | cabazitaxel prednisone octreotide pamo... questionnaire a... octreotide acet... | 18 Years - | University of Southern California | |
| Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) | NCT01830231 | Urothelium Tran... | Cabazitaxel Vinflunine | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy | NCT01437488 | Urothelial Carc... | Cabazitaxel Neulasta CT Scan Blood Draw | 18 Years - | Thomas Jefferson University | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) | NCT03050866 | Circulating Tum... Metastatic Pros... | Cabazitaxel Antihistamine Corticosteroid H2 antagonist Antiemetic | 18 Years - | Erasmus Medical Center | |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | NCT01335204 | Prostate Cancer Prostatic Neopl... | Cabazitaxel plu... | 18 Years - | Medical University of South Carolina | |
| CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | NCT03934840 | Prostate Cancer | Cabazitaxel Carboplatin Abiraterone Prednisone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | NCT01866449 | Glioblastoma Mu... | Cabazitaxel | 18 Years - | University of Ulm | |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | NCT02035124 | Advanced Prosta... | BKM 120 Cabazitaxel | 18 Years - | SCRI Development Innovations, LLC | |
| The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation | NCT01981668 | Prostatic Neopl... | cabazitaxel | 18 Years - | Nova Scotia Cancer Centre | |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | NCT02035124 | Advanced Prosta... | BKM 120 Cabazitaxel | 18 Years - | SCRI Development Innovations, LLC | |
| Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | NCT02478502 | Testicular Canc... | cabazitaxel | 18 Years - | University Hospital, Akershus | |
| Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC | NCT01913067 | Brain Metastasi... Breast Cancer Non Small Cell ... | Cabazitaxel Contrast-enhanc... | 18 Years - | Jules Bordet Institute | |
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Ph II Cabazitaxel DD Liposarcoma | NCT01913652 | Dedifferentiate... | Cabazitaxel | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | NCT01934894 | Metastatic Brea... | cabazitaxel lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) | NCT02166658 | Breast Cancer Lung Cancer Recurrent Brain... Progressive Bra... | Cabazitaxel | 18 Years - | AIO-Studien-gGmbH | |
| Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) | NCT05563558 | Prostate Cancer... | Pembrolizumab Carboplatin Cabazitaxel | 18 Years - | Fundacion Oncosur | |
| Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer | NCT03327662 | Adenocarcinoma ... | Active CTC Asse... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | NCT03934840 | Prostate Cancer | Cabazitaxel Carboplatin Abiraterone Prednisone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs | NCT02621190 | Prostatic Neopl... | cabazitaxel | 18 Years - | Erasmus Medical Center | |
| Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors | NCT01447225 | Solid Tumors | MM-121 Carboplatin Pemetrexed Cabazitaxel Gemcitabine | 18 Years - | Merrimack Pharmaceuticals | |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | NCT01620242 | Recurrent Head ... Metastatic Head... | Cabazitaxel | 18 Years - | UNICANCER | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs | NCT02621190 | Prostatic Neopl... | cabazitaxel | 18 Years - | Erasmus Medical Center | |
| Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor | NCT01001221 | Neoplasms, Mali... | cabazitaxel gemcitabine | 18 Years - | Sanofi | |
| Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | NCT02903160 | Prostate Cancer | Abiraterone ace... Prednisone Radium-223 dich... cabazitaxel Carboplatin Enzalutamide | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic | NCT03101046 | Prostate Carcin... Castration-resi... Circulating Tum... Chemotherapy | Cabazitaxel Docetaxel | 18 Years - | UNICANCER | |
| Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer | NCT05340374 | Metastatic Cast... mCRPC | Cabazitaxel 177Lu-PSMA-617 | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes | NCT01693549 | Breast Cancer | Cabazitaxel | 18 Years - 75 Years | Hellenic Cooperative Oncology Group | |
| Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | NCT03048942 | HER2 Negative M... | Cabazitaxel Paclitaxel | 18 Years - 99 Years | University Hospitals Bristol and Weston NHS Foundation Trust | |
| A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | NCT02985957 | Prostate Cancer | Nivolumab Ipilimumab Cabazitaxel Prednisone | 18 Years - | Bristol-Myers Squibb | |
| A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis | NCT03114254 | Penile Neoplasm | Cabazitaxel | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines | NCT03257891 | Adrenocortical ... | Cabazitaxel | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis | NCT03258320 | Prostate Cancer... | Cabazitaxel, Do... | 40 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) | NCT01779479 | Primary Breast ... | Cabacitaxel Paclitaxel | 18 Years - | German Breast Group | |
| Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer | NCT01956149 | Gastric Cancer | Cabazitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | NCT01254279 | Prostate Cancer... | CABAZITAXEL | 18 Years - | Sanofi | |
| Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | NCT01845792 | Prostate Cancer | Cabazitaxel wit... Cabazitaxel | 18 Years - 95 Years | University of Colorado, Denver | |
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Cabazitaxel in Relapsed and Metastatic NSCLC | NCT01852578 | NSCLC | Cabazitaxel | 18 Years - | Hellenic Oncology Research Group | |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | NCT01620242 | Recurrent Head ... Metastatic Head... | Cabazitaxel | 18 Years - | UNICANCER | |
| CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC. | NCT03381326 | Prostate Cancer Metastatic Canc... Castration-resi... Circulating Tum... | blood and FFPE ... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | NCT01500720 | Small Cell Lung... | Cabazitaxel Topotecan | 18 Years - | Sanofi | |
| Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | NCT03295565 | Prostate Cancer... Metastasis | Cabazitaxel Abiraterone Enzalutamide | 18 Years - | The Netherlands Cancer Institute | |
| Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer | NCT01750866 | Castrate-resist... | Cabazitaxel Prednisone Granulocyte col... | 75 Years - | Case Comprehensive Cancer Center | |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | NCT06085729 | Prostate Cancer | ADI-PEG 20 Cabazitaxel Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | NCT02985957 | Prostate Cancer | Nivolumab Ipilimumab Cabazitaxel Prednisone | 18 Years - | Bristol-Myers Squibb | |
| Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic | NCT03101046 | Prostate Carcin... Castration-resi... Circulating Tum... Chemotherapy | Cabazitaxel Docetaxel | 18 Years - | UNICANCER | |
| A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer | NCT01541007 | Metastatic Cast... | Cabazitaxel weekly cabazita... | 18 Years - | Karolinska University Hospital | |
| A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer | NCT04709276 | Metastatic Pros... Metastatic Pros... | Nivolumab Ipilimumab Carboplatin Cabazitaxel | 18 Years - | Duke University | |
| CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | NCT03934840 | Prostate Cancer | Cabazitaxel Carboplatin Abiraterone Prednisone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer | NCT01956149 | Gastric Cancer | Cabazitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) | NCT03050866 | Circulating Tum... Metastatic Pros... | Cabazitaxel Antihistamine Corticosteroid H2 antagonist Antiemetic | 18 Years - | Erasmus Medical Center | |
| Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | NCT01866449 | Glioblastoma Mu... | Cabazitaxel | 18 Years - | University of Ulm | |
| CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | NCT03356912 | Prostate Cancer Castration-resi... | Cabazitaxel Prednisone | 18 Years - | Consorzio Oncotech | |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer | NCT03392428 | Cancer of the P... Metastatic Canc... | 177Lu-PSMA617 Cabazitaxel | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Cabazitaxel and Radiation For Patients With Prostate Cancer | NCT01650285 | Prostate Cancer | Cabazitaxel | 18 Years - | Brown University | |
| Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT02844582 | Hormone-Resista... Stage IV Prosta... | Cabazitaxel Prednisone | 18 Years - | University of California, Davis | |
| Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) | NCT05563558 | Prostate Cancer... | Pembrolizumab Carboplatin Cabazitaxel | 18 Years - | Fundacion Oncosur | |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | NCT01469338 | Diarrhea Hormone-resista... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | cabazitaxel prednisone octreotide pamo... questionnaire a... octreotide acet... | 18 Years - | University of Southern California | |
| Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | NCT03043989 | Prostate Cancer | Docetaxel Cabazitaxel Clarithromycin | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
